5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: Can we afford to wait for 'best evidence'?

被引:22
作者
Giannini, EG
Kane, SV
Testa, R
Savarino, V
机构
[1] Univ Genoa, Dept Internal Med, Gastroenterol Unit, I-16132 Genoa, Italy
[2] Univ Chicago, Dept Med, Gastroenterol & Nutr Sect, Chicago, IL 60637 USA
关键词
5-ASA; chemoprevention; cirrhosis; colorectal cancer; inflammatory bowel disease; mesalazine;
D O I
10.1016/j.dld.2005.02.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Patients with inflammatory bowel disease have a higher risk of developing colorectal cancer. The main risk factors for colorectal cancer are not suitable targets for therapeutic intervention, and primary chemoprevention is an intriguing therapeutic option. The analogies between acetyl-salycilic acid and 5-amino-salycilic acid, and the results obtained by using acetyl-salycilic acid as a chernopreventive agent in patients with sporadic colorectal cancer have prompted the study of potential chernopreventive effects of 5-amino-salycilic acid in inflammatory bowel disease. The results of both epidemiological and experimental studies have shown that Iona-term 5-amino-salycilic acid treatments appear to have a chemopreventive effect. The evidence for this effect is provided by retrospective and case-control studies whose results, however, do not reach the highest grades for evidence-based recommendations. Nevertheless, these results are supported by a series of experimental studies demonstrating the multiplicity of actions of 5-amino-salycilic acid. Although data regarding the chernopreventive effect of 5-amino-salycilic acid may not be rigorous enough to meet the criteria for the highest evidence-based medicine recommendations, we feel that the argument to wait until we have Grade A evidence is not necessarily rational in this case, because discontinuation of 5-amino-salycilic acid treatment to perform a randomised controlled trial would be unethical secondary to their proven efficacy for maintenance treatment. (c) 2005 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:723 / 731
页数:9
相关论文
共 87 条
[1]   Aminosalicylates: Potential antineoplastic actions in colon cancer prevention [J].
Allgayer, H ;
Kruis, W .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (02) :125-131
[2]   Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease [J].
Allgayer, H .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 :10-14
[3]   SUPEROXIDE, HYDROXYL AND FATTY-ACID RADICAL SCAVENGING BY AMINOSALICYLATES - DIRECT EVALUATION WITH ELECTRON-SPIN-RESONANCE SPECTROSCOPY [J].
ALLGAYER, H ;
HOFER, P ;
SCHMIDT, M ;
BOHNE, P ;
KRUIS, W ;
GUGLER, R .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (02) :259-262
[4]  
Anti M, 1998, ITAL J GASTROENTEROL, V30, pS276
[5]   Nuclear receptors -: I.: PPARγ in the gastrointestinal tract:: gain or pain? [J].
Auwerx, J .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2002, 282 (04) :G581-G585
[6]  
Bansal P, 1996, AM J GASTROENTEROL, V91, P44
[7]  
Bantel H, 2000, AM J GASTROENTEROL, V95, P3452
[8]   A randomized trial of aspirin to prevent colorectal adenomas [J].
Baron, JA ;
Cole, BF ;
Sandler, RS ;
Haile, RW ;
Ahnen, D ;
Bresalier, R ;
McKeown-Eyssen, G ;
Summers, RW ;
Rothstein, R ;
Burke, CA ;
Snover, DC ;
Church, TR ;
Allen, JI ;
Beach, M ;
Beck, GJ ;
Bond, JH ;
Byers, T ;
Greenberg, ER ;
Mandel, JS ;
Marcon, N ;
Mott, LA ;
Pearson, L ;
Saibil, F ;
van Stolk, RU .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) :891-899
[9]  
BEDI A, 1995, CANCER RES, V55, P1811
[10]   Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial [J].
Benamouzig, R ;
Deyra, J ;
Martin, A ;
Girard, B ;
Jullian, E ;
Piednoir, B ;
Couturier, D ;
Coste, T ;
Little, J ;
Chaussade, S .
GASTROENTEROLOGY, 2003, 125 (02) :328-336